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Abstract 
Acquired haemophilia A and severe acquired achalasia are both very rare conditions with 
unknown aetiology. Haemophilia A is a haemorrhagic disease induced by deficiency or 
malfunction of coagulation factor VIII. Congenital haemophilia is an inherited disease 
transmitted by the mother through X-linked inheritance and primarily affects males. 
However, acquired haemophilia A is a serious, sudden-onset, autoimmune disease that 
affects either sex. In addition, achalasia is a disease of the oesophagus caused by abnormal 
function of the nerves and muscles. It causes swallowing difficulties due to the inability of 
the lower oesophageal sphincter to relax during swallowing, leading to dysphagia, 
regurgitation and chest pain. In this report, we describe the case of a patient with severe, 
newly diagnosed, acquired haemophilia A with long-standing, recurrent achalasia; the 
achalasia had recurred 3 times despite complete and proper surgical fixation. Acquired 
haemophilia A is treated with immunosuppressive therapy. High-dose steroid therapy was 
administered for 7 months, during which the patient responded well; moreover, the 
achalasia did not recur for more than 2 years. The response of the achalasia to 
immunosuppressive therapy suggests that achalasia may be an autoimmune disorder and 
that there may be an association between both diseases. The findings of the present case 
suggest that achalasia may favourably respond to steroid therapy as a first-line treatment 
prior to surgery. 
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Introduction 
Haemophilia may be an acquired or congenital disorder. The congenital forms of 
haemophilia A and B are caused by low levels of coagulation factor VIII (FVIII) and 
coagulation factor IX, respectively. These protein factors are essential for the 
generation of thrombin, which is required to stabilise the primary platelet plug and 
thus help control bleeding. FVIII deficiency may also be caused by autoantibodies 
directed against the FVIII molecule, leading to acquired haemophilia. Congenital 
haemophilia manifests with spontaneous haemorrhage in muscle and joints and, 
rarely, in the skin and soft tissues. Acquired haemophilia manifests with extensive 
subcutaneous extravasations and mucosal haemorrhages in the gastrointestinal tract, 
urinary tract and female genital tract, and extensive, painful, intramuscular hematomas 
[1]. Severe haemophilia A affects approximately 1 in 10,000 males, and severe 
haemophilia B affects approximately 1 in 50,000 males [2]. Acquired haemophilia is 
less common: evaluation of the frequency in the UK identified an unbiased cohort of 
172 patients with an incidence of 1.48 per million per year. Achalasia is a rare disease 
of the nerves and muscles of the oesophagus caused by failure of the oesophageal 
muscles to relax during swallowing and the inability of the lower oesophageal 
sphincter to open. This difficulty in swallowing prevents food from passing into the 
stomach [3]. Achalasia comprises 3 types, based on the severity of the symptoms: 
hypermotile, hypomotile and amotile. The disease can occur at any age, with a similar 
rate in men and women, but it is usually diagnosed between 25 and 60 years of age. It 
is characterised predominantly by dysphagia to solids and liquids, bland regurgitation 
and chest pain [4]. It has an annual incidence of approximately 1 in 100,000 and a 
prevalence rate of 1 in 10,000. Complications of achalasia include weight loss, 
aspiration pneumonia and oesophagitis caused by irritation from collection of food and 
fluids in the oesophagus. There is also a risk of cancer of the oesophagus in patients 
with long-standing achalasia. Some reports have described achalasia as an autoimmune 
disorder [5], and there is evidence suggesting that different autoimmune disorders may 
be associated in the same patient. In this case report, we describe a patient with 
acquired haemophilia A associated with acquired achalasia. We explore the possibility 
that autoimmunity is an aetiological factor for both diseases. 
Case Report 
A 27-year-old woman presented to our hospital in April 2010 with right forearm bruises of 
approximately 4 cm × 3 cm; she had no predisposing factors or history of bleeding tendency. 
Possible trauma was diagnosed. The next day, the bruises grew larger, and the patient sought 
another consultation at a private general medical centre, where the diagnosis of a possible insect 
bite was made. The patient was concerned about the progressively increasing size of the bruises, 
which reached approximately 15 cm × 5 cm over 2 days. Therefore, she visited the haematology 
outpatient department of our hospital 3 days after the bruises were first noticed. Haematological 
investigations at presentation revealed normal results for liver enzymes, immunoglobulin profile 
and antinuclear factor. A virology screening study showed negative results for hepatitis C, hepatitis B 
and human immunodeficiency virus. C4 level was 0.16 g/l (normal 0.16–0.47), C3 level was 0.90 g/l 
(normal 0.88–2.01), and C-reactive protein level was 5.6 mg/l (normal 0.0–8.0). The level of 
rheumatoid factor was <20 IU/ml (normal 0–20). The erythrocyte sedimentation rate value was 
5 mm/h (normal 0–20). The patient’s blood group was O positive. Coagulation profile results obtained 
on presentation were as follows: prothrombin time was 13.9 s (reference range 10.0–13.0), bleeding 
time was 2.10 min (reference range 1.00–4.00), von Willebrand factor Ag-O was 64.4% (reference 
range 41.1–125.9), von Willebrand factor ACTO was 48.3% (reference range 38.0–125.2), and 
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fibrinogen was 3.39 g/l (normal 2.20–4.96). Results of the activated partial thromboplastin time 
(APTT) test (a before-and-after, mixed, study test) showed that prolonged APTT did not correctly 
adjust when adding normal plasma to patient plasma, as it would in the case of congenital 
haemophilia A (table 1). 
The patient had a history of recurrent acquired achalasia since 2000 (aged 16 years), when she 
exhibited symptoms of dysphagia for solids and liquids. She presented to medical casualty 7 times 
with choking and difficulty swallowing. In early 2003, she underwent gastrointestinal endoscopy 
for the first time, which did not indicate any abnormal findings. However, barium swallow showed 
abnormal barium retention for more than 15 min at the distal oesophagus. Radiological findings 
confirmed the diagnosis of achalasia cardia (fig. 1) and excluded other oesophageal motility 
disorders. She subsequently underwent oesophageal manometry. Following the diagnosis of achalasia 
cardia, she was transferred to Bupa Cromwell Hospital, where further tests confirmed this diagnosis. 
A Heller myotomy was performed, after which the symptoms of dysphagia resolved. 
In 2004, the patient relapsed and underwent balloon dilatation at Bupa Cromwell Hospital, but 
only partial improvement was noted. In 2005, she had recurrent episodes of dysphagia grade 3. 
Oesophageal manometry was repeated and revealed recurrent achalasia. In 2006, she had recurrent 
episodes of dysphagia during pregnancy. She was advised to undergo balloon dilatation after delivery. 
In 2007, she relapsed again and underwent Nissen fundoplication without success. In 2008, the 
achalasia relapsed, and she underwent a second balloon dilatation but experienced no improvement. 
In January 2010, she underwent another Nissen fundoplication, oesophageal myotomy, and a Toupet 
fundoplication at the Mayo Clinic in the United States. Her symptoms improved, but at presentation to 
our clinic in April 2010 she had arm bruises and recurrent discomfort in swallowing. 
Upon diagnosis of acquired autoimmune haemophilia, the patient was administered prednisolone 
at a dose of 1 mg/kg (50 mg) for 1 week. She showed good response (table 2), and the dose was then 
tapered by reducing prednisolone by 10 mg each week until week 4, after which time a dose of 10 mg 
was maintained for 6 months. The total period of steroid therapy was 7 months. The patient’s 
achalasia symptoms improved after initiation of corticosteroid therapy for acquired haemophilia, and 
her dysphagia has been in complete remission for more than 2 years without relapse. 
Discussion 
Human autoimmune diseases are generally more common in females than in males. 
Many chronic autoimmune diseases have a relapsing-remitting course. Individuals 
with a particular autoimmune disease have an increased risk of developing other 
autoimmune diseases. However, there is increasing evidence that another important 
genetic component increases the susceptibility to ‘autoimmunity-in-general’ [6]. 
Cross-reacting autoantibodies targeting an epitope have the potential to spread the 
autoimmune response to other RNA-binding proteins through molecular mimicry; 
subsequently, intramolecular spreading to these specific proteins can occur [7]. 
In the present case, the patient had chronic, relapsing, acquired achalasia from 
the age of 16 years. Ten years after the first manifestation of achalasia, she developed 
severe autoimmune acquired haemophilia A, which was treated promptly and 
aggressively with high-dose steroids for 7 months. During the 7 months of steroid 
treatment and the nearly 2 years since cessation of treatment, the achalasia and the 
haemophilia A have remained in remission. 
In individuals with autoimmune diseases, there is an increased risk of developing 
other autoimmune diseases mediated by additional or cross-reacting autoantibodies. 
Therefore, we assume this patient had autoimmune acquired achalasia. We believe 
that, 10 years after the first manifestation of achalasia, she developed another 
well-known autoimmune antibody against FVIII, leading to acquired haemophilia A. 
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The two disorders may be targeted by a cross-reacting autoantibody; however, we have 
no indication of the relevant autoimmune target in achalasia. The occurrence of the two 
disorders in one patient suggests that achalasia is also an autoimmune disorder. This 
is supported by the patient’s long-standing remission after steroid therapy. Moreover, 
achalasia has previously been reported in association with other autoimmune 
disorders, such as autoimmune thyrotoxicosis and autoimmune polyglandular 
polymyositis. Thus, autoimmune disorders can share the cross-reacting antibody [8]. 
The treatment of acquired haemophilia is generally similar to other autoimmune 
disorders and includes immunosuppressive treatment to eliminate the inhibitory 
antibodies. Typical treatment, based on the results of a randomised clinical trial, 
involves administration of prednisolone at a dose of 1 mg/kg with or without orally 
administered cyclophosphamide (50–100 mg/day) [9]. The use of rituximab may be 
considered for initial therapy in cases where the initial antibody titre is high [10]. 
Porcine factor VIII (Hyate: C) is a safe and effective treatment for bleeding episodes 
associated with acquired haemophilia [11]; however, azathioprine therapy may be 
preferred for women of child-bearing age. Treatment should be continued for up to 
6 weeks with regular patient assessment. Most patients will respond well to this 
treatment combination. However, relapse can occur when the drugs are discontinued 
or the dose is reduced. Infusions of immunoglobulin may also be beneficial. A 
prospective, non-randomised trial involving immunoglobulin therapy assessed the 
response to doses of 1.0 g per day for 2 days or 0.4 g for 5 days in patients with 
acquired haemophilia. A 25% reduction in inhibitor titre was observed in 8 of 16 
assessable patients [12]. However, the use of other immunosuppressive agents should 
also be considered. 
Conclusion 
Our patient experienced an almost annual relapse of achalasia cardia since 
the age of 16, but achieved complete remission for more than 2 years following 
corticosteroid therapy, which was administered for the associated severe acquired 
haemophilia A. This remission suggests that acquired achalasia may also be an 
autoimmune disorder, similar to acquired haemophilia A, and that corticosteroids or 
other immunosuppressive therapy may be the appropriate treatment prior to surgical 
intervention. However, further observational studies are required to document this 
relationship, confirm this association and elucidate additional insights into the 
aetiology of this condition. 
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Table 1. Mixed study results 
   
   
 Result Reference range 
   
   
APTT patient, s 62 25–35 
APTT control, s 36 25–35 
P+C (pre-incubation), s 65 25–35 
P+C (2 h post-incubation), s 88 25–35 
   
   
 
 
Table 2. Normal values for APTT (25–35 s), FVIII Act (50–150%) and VW Act (38.2–125.2%) 
       
       
Duration INR APTT Mixed FVIII Act VW Act VW Act 
       
       
At presentation 1.24 71 40 – –  
After 1 day 1.07 62 42 1.98 48.3 64.4 
After 2 weeks 1.07 40 36 39.80 –  
After 3 months 1.19 29 – 144 –  
       
       
 
 
 
 
 
Fig. 1. Barium meal study showing significant blockage at the lower oesophagus just above the 
gastro-oesophageal junction. There is evidence of a small, tapering, rat-tail appearance associated 
with dilatation of the oesophagus lumen with marked fluid level. No extraluminal leak was noted. 
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